Try our Advanced Search for more refined results

Expert Analysis

Between You And Me: FDA Comments Not Disclosure Events

Law360, New York (April 23, 2012, 1:14 PM EDT) -- In an important ruling dismissing a comprehensive securities class action complaint against Genzyme Corp., the U.S. District Court for the District of Massachusetts held last week that regulatory comments and inspectional observations provided by the U.S. Food and Drug Administration (FDA) to pharmaceutical companies like Genzyme — including commentary supplied on FDA Form 483 — are of "questionable materiality" and are not automatically required to be disclosed by regulated issuers....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections

Law Firms

Companies

Government Agencies

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!